TEANECK, N.J., March 1, 2012 /PRNewswire/ -- Herborium Group,
Inc., (Pink Sheets: HBRM) www.herborium.com, a Botanical
Therapeutics® company, announce today a plan to commercialize
its sexual health proprietary Botanical Therapeutics® in 2012. The
market for pharmaceutical grade sexual health products is over 3.2
billion worldwide with Viagra (Pfizer), Cialis (Eli Lilly) and
Levitra (Bayer) leading market share. The market for natural sexual
health products is estimated to be over $1.5
billion and growing. The rising costs of pharmaceutical
grade sexual health drugs together with some safety
concerns drive consumers to look for alternatives in the
market for natural sexual health products.
In addition there is a growing need for women sexual health
products. In fact the female sexual enhancement industry is
expected to grow into a multibillion dollar business. Long
considered a taboo subject, women's sexuality is now openly
discussed and portrayed on television, in magazines, and on the
internet. Most importantly, women themselves are becoming
increasingly aware of their sexuality and their sexual health.
First-quarter sales of personal lubricants soared 32% to
$41.2 million, according to
Information Resources Inc. There is no Viagra comparative product
on the market for women.
Dr. Agnes Olszewski, Chairman and
CEO of Herborium, stated: "We believe that this is the right time
to commercialize our all herbal, proprietary products for men and
women. There is nothing on the market as our systemic all herbal
product for women. Unlike many supplements claiming to improve
sexual performance and libido both our products include only herbal
ingredients recognized for their safety. Both products developed by
Herborium are based on a combination of Principles of Traditional
Chinese Medicine and modern sexual health science, have confirmed
up to 98% efficacy and improve performance and experience for those
men and women with sexual performance problems and those seeking
recreational sexual enhancement. Products have no know adverse
effects."
"By combining unique characteristics of Herborium sexual health
Botanical Therapeutics® with our social media marketing strategy
and growing demand and awareness regarding sexual health, we expect
our products to gain market acceptance and revenue generating
status in 2012," concluded Dr. Olszewski.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company,
focuses on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company uses clinical validation to establish
and maintain a differential advantage. The company sales its
products in the US and Europe. For
more information, please visit www.herborium.com and
www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or
alter forward-looking statements as the result of new information
or future events. The Company urges investors to review the risks
and uncertainties contained within its filings with the OTC Markets
and/or Securities and Exchange Commission.
For more information please inquire:
Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.
